Additional clinical trials using local administration of SPP (NanoPac®) were completed in recurrent ovarian cancer [3, 4], focal prostate cancer (Clinicaltrials.gov identifier NCT03077659), and pancreatic mucinous cysts (Clinicaltrials.gov identifier NCT03188991) [5] and are ongoing in IT injection of lung cancer (Clinicaltrials.gov identifier NCT04314895), focal prostate cancer (Clinicaltrials.gov identifier NCT04221828), and locally advanced pancreatic cancer (Clinicaltrials.gov identifier NCT3077685). This evidence concerns the gene HM13 and prostate cancer.